RxDoctor Payments Data

Maureen Alexander, MD

Ophthalmology · Austin, TXNPI 1275619496

Payments from drug & device makers

$6,626in general payments, 2019–2025

Across 27 payments — averaging $245.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$4K
  • AbbVie$422
  • Johnson & Johnson Surgical Vision, Inc.$411
  • Aerie Pharmaceuticals, Inc.$357
  • Amgen$249
  • Bausch & Lomb Americas Inc.$245
  • plus $808 from 8 others

What the payments were for

  • Food & beverage$2,48237%
  • Education$110%
  • Other$4,13362%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,626 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$57,892
Medicare patients
213
Services billed
703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost105$56,807
RestasisCyclosporine29$38,122
Brimonidine Tartrate65$9,045
RocklatanNetarsudil Mesylat/Latanoprost21$8,963
CombiganBrimonidine Tartrate/Timolol27$8,810
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol43$8,733
Travoprost41$7,569
SimbrinzaBrinzolamide/Brimonidine Tart15$6,980
Brinzolamide15$4,199
Betaxolol Hcl13$1,489
Bimatoprost12$1,431
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat56$1,173
Dorzolamide Hcl41$936
Latanoprost79$749
Levobunolol Hcl23$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$422$103,739161 claims
Aerie Pharmaceuticals, Inc.Rocklatan$357$8,96321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →